Literature DB >> 14656070

Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features.

Christine E Fuller1, Robert E Schmidt, Kevin A Roth, Peter C Burger, Bernd W Scheithauer, Ruma Banerjee, Kathryn Trinkaus, Richard Lytle, Arie Perry.   

Abstract

Gliomas with hybrid oligodendroglial/astrocytic features are diagnostically problematic, and our ability to predict tumor behavior is limited. Some likely represent intermingled mixed oligoastrocytomas (MOAs), though precise diagnostic criteria and specific markers for this lesion are lacking. From the files at Washington University (1987-2000), 155 "ambiguous" glioma/intermingled MOA candidates were independently classified and graded by 5 neuropathologists, with consensus-derived pure oligodendrogliomas and astrocytomas excluded from further study. The 90 remaining cases (grades II = 29, III = 44, IV = 17) were analyzed by FISH on formalin-fixed, paraffin-embedded sections. Detectable deletions included combined 1p/19q (9%), solitary 19q (22%), PTEN/DMBT1 (26%), and p16 (32%). EGFR amplification was found in 11%. Patients were followed until death (47%) or a median of 3.3 years. Similar to prior glioma series, patient age (p < 0.0001) and tumor grade (p < 0.0001) were strongly associated with survival times. EGFR amplification (p = 0.0007) and deletions of PTEN/ DMBT1 (p = 0.016) or p16 (p = 0.014), either individually or as a group (p = 0.04), portended a shorter median survival compared with tumors lacking these alterations. We conclude that 1) distinct genetic subsets are identifiable by FISH in morphologically ambiguous gliomas, and 2) both histological grading and molecular analysis yield prognostically useful information.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656070     DOI: 10.1093/jnen/62.11.1118

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  35 in total

1.  Molecular profile of oligodendrogliomas in young patients.

Authors:  Vaishali Suri; Prerana Jha; Shipra Agarwal; Pankaj Pathak; Mehar Chand Sharma; Vikas Sharma; Sudhanshu Shukla; Kumaravel Somasundaram; Ashok Kumar Mahapatra; Shashank Sharad Kale; Chitra Sarkar
Journal:  Neuro Oncol       Date:  2011-10       Impact factor: 12.300

Review 2.  Molecular diagnostics: techniques and recommendations for 1p/19q assessment.

Authors:  Adelheid Woehrer; Johannes A Hainfellner
Journal:  CNS Oncol       Date:  2015-11-06

3.  1p/19q-driven prognostic molecular classification for high-grade oligodendroglial tumors.

Authors:  Haihui Jiang; Zhe Zhang; Xiaohui Ren; Wei Zeng; Wenqing Jia; Junmei Wang; Song Lin
Journal:  J Neurooncol       Date:  2014-08-24       Impact factor: 4.130

4.  Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.

Authors:  Birgit Geoerger; Darren Hargrave; Fabienne Thomas; Anna Ndiaye; Didier Frappaz; Felipe Andreiuolo; Pascale Varlet; Isabelle Aerts; Riccardo Riccardi; Timothy Jaspan; Etienne Chatelut; Marie-Cecile Le Deley; Xavier Paoletti; Christian Saint-Rose; Pierre Leblond; Bruce Morland; Jean-Claude Gentet; Valérie Méresse; Gilles Vassal
Journal:  Neuro Oncol       Date:  2010-10-25       Impact factor: 12.300

5.  Intratumoral patterns of clonal evolution in gliomas.

Authors:  Ana Luísa Vital; Maria Dolores Tabernero; Inês Crespo; Olinda Rebelo; Hermínio Tão; Fernando Gomes; Maria Celeste Lopes; Alberto Orfao
Journal:  Neurogenetics       Date:  2009-09-17       Impact factor: 2.660

6.  Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas.

Authors:  Sergei I Bannykh; C Claus Stolt; Jung Kim; Arie Perry; Michael Wegner
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

7.  Application of brush cytology for FISH-based detection of 1p/19q codeletion in oligodendroglial tumors.

Authors:  Irena Srebotnik-Kirbiš; Clara Limbäck-Stokin
Journal:  J Neurooncol       Date:  2016-07-12       Impact factor: 4.130

8.  Something old and something new about molecular diagnostics in gliomas.

Authors:  Craig Horbinski
Journal:  Surg Pathol Clin       Date:  2012-12-01

9.  How molecular testing can help (and hurt) in the workup of gliomas.

Authors:  Kenneth Clark; Zoya Voronovich; Craig Horbinski
Journal:  Am J Clin Pathol       Date:  2013-03       Impact factor: 2.493

10.  Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis.

Authors:  Luciana Wernersbach Pinto; Maria Betania Mahler Araújo; Andre L Vettore; Liana Wernersbach; André Campana C Leite; Leila Maria C Chimelli; Fernando Augusto Soares
Journal:  Virchows Arch       Date:  2008-05       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.